NL8403979A - Antibiotische verbinding, werkwijze voor de bereiding daarvan, alsmede preparaten die deze bevatten. - Google Patents

Antibiotische verbinding, werkwijze voor de bereiding daarvan, alsmede preparaten die deze bevatten. Download PDF

Info

Publication number: NL8403979A
Authority: NL; Netherlands
Prior art keywords: stearate; erythromycin; acetyl; formula; preparation
Prior art date: 1984-01-06

Application number

NL8403979A

Other languages

English (en)

Dutch (nl)

Original Assignee

Orion Yhtymae Oy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-01-06

Filing date

1984-12-31

Publication date

1985-08-01

1984-12-31 Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy

1985-08-01 Publication of NL8403979A publication Critical patent/NL8403979A/nl

Links

150000001875 compounds Chemical class 0.000 title claims description 18
238000002360 preparation method Methods 0.000 title claims description 18
238000000034 method Methods 0.000 title claims description 13
230000003115 biocidal effect Effects 0.000 title claims description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 39
229960004142 erythromycin stearate Drugs 0.000 claims description 29
-1 acetyl erythromycin stearate Chemical compound 0.000 claims description 26
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 22
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
239000004480 active ingredient Substances 0.000 claims description 7
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
238000006243 chemical reaction Methods 0.000 claims description 5
150000002148 esters Chemical class 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 4
239000004615 ingredient Substances 0.000 claims description 4
239000003208 petroleum Substances 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
238000009835 boiling Methods 0.000 claims description 3
239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
238000002955 isolation Methods 0.000 claims description 3
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
239000008108 microcrystalline cellulose Substances 0.000 claims description 3
229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
229920002261 Corn starch Polymers 0.000 claims description 2
229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 2
150000008041 alkali metal carbonates Chemical class 0.000 claims description 2
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
150000001342 alkaline earth metals Chemical class 0.000 claims description 2
239000008120 corn starch Substances 0.000 claims description 2
235000021552 granulated sugar Nutrition 0.000 claims description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
239000003960 organic solvent Substances 0.000 claims 2
239000000945 filler Substances 0.000 claims 1
239000007788 liquid Substances 0.000 claims 1
239000000314 lubricant Substances 0.000 claims 1
235000019359 magnesium stearate Nutrition 0.000 claims 1
238000000926 separation method Methods 0.000 claims 1
239000007787 solid Substances 0.000 claims 1
YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 13
238000010521 absorption reaction Methods 0.000 description 10
229960003276 erythromycin Drugs 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
239000000243 solution Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
229960003203 erythromycin estolate Drugs 0.000 description 4
AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 4
239000008187 granular material Substances 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
231100000304 hepatotoxicity Toxicity 0.000 description 3
230000007056 liver toxicity Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
239000012346 acetyl chloride Substances 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000007888 film coating Substances 0.000 description 2
238000009501 film coating Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000008213 purified water Substances 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
RJUFATJOENABQE-UHFFFAOYSA-N (2,2,2-trichloro-1-diphenoxyphosphorylethyl) acetate Chemical compound C=1C=CC=CC=1OP(=O)(C(C(Cl)(Cl)Cl)OC(=O)C)OC1=CC=CC=C1 RJUFATJOENABQE-UHFFFAOYSA-N 0.000 description 1
NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241001530392 Aphos Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
238000011785 NMRI mouse Methods 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000009640 blood culture Methods 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229960004213 erythromycin lactobionate Drugs 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
231100000334 hepatotoxic Toxicity 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000002547 new drug Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000003825 pressing Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000008279 sol Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Coloring (AREA)

NL8403979A 1984-01-06 1984-12-31 Antibiotische verbinding, werkwijze voor de bereiding daarvan, alsmede preparaten die deze bevatten. NL8403979A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK5884A DK149776C (da)	1984-01-06	1984-01-06	Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
DK5884		1984-01-06

Publications (1)

Publication Number	Publication Date
NL8403979A true NL8403979A (nl)	1985-08-01

Family

ID=8089251

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8403979A NL8403979A (nl)	1984-01-06	1984-12-31	Antibiotische verbinding, werkwijze voor de bereiding daarvan, alsmede preparaten die deze bevatten.

Country Status (38)

Country	Link
US (1)	US4599326A (2)
JP (1)	JPS60158197A (2)
KR (1)	KR900006237B1 (2)
AT (1)	AT386414B (2)
AU (1)	AU565688B2 (2)
BE (1)	BE901411A (2)
BG (1)	BG43189A3 (2)
CA (1)	CA1224461A (2)
CH (1)	CH666275A5 (2)
CS (1)	CS247191B2 (2)
CY (1)	CY1462A (2)
DE (1)	DE3500179A1 (2)
DK (1)	DK149776C (2)
ES (1)	ES8605818A1 (2)
FI (1)	FI77249C (2)
FR (1)	FR2557878B1 (2)
GB (1)	GB2152502B (2)
HK (1)	HK11590A (2)
HU (1)	HU196221B (2)
IE (1)	IE57967B1 (2)
IL (1)	IL73885A (2)
IS (1)	IS2968A7 (2)
IT (1)	IT1184304B (2)
KE (1)	KE3841A (2)
LU (1)	LU85721A1 (2)
MA (1)	MA20316A1 (2)
MX (1)	MX156277A (2)
NL (1)	NL8403979A (2)
NO (1)	NO160263C (2)
NZ (1)	NZ210606A (2)
PH (1)	PH22471A (2)
PL (1)	PL144349B1 (2)
PT (1)	PT79777B (2)
RO (1)	RO91262B (2)
SE (1)	SE461854B (2)
SU (1)	SU1410866A3 (2)
YU (1)	YU44485B (2)
ZA (1)	ZA8410143B (2)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4874614A (en) *	1985-03-25	1989-10-17	Abbott Laboratories	Pharmaceutical tableting method
US4863741A (en) *	1985-03-25	1989-09-05	Abbott Laboratories	Tablet composition for drug combinations
JP3382159B2 (ja) *	1998-08-05	2003-03-04	株式会社東芝	情報記録媒体とその再生方法及び記録方法
US10004729B2 (en)	2002-07-05	2018-06-26	Collegium Pharmaceutical, Inc.	Tamper-resistant pharmaceutical compositions of opioids and other drugs
US7399488B2 (en) *	2002-07-05	2008-07-15	Collegium Pharmaceutical, Inc.	Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US8840928B2 (en)	2002-07-05	2014-09-23	Collegium Pharmaceutical, Inc.	Tamper-resistant pharmaceutical compositions of opioids and other drugs
KR20060108692A (ko) *	2003-10-31	2006-10-18	알자 코포레이션	메트포르민의 개선된 흡수를 위한 조성물 및 제형
CA2916869A1 (en)	2004-06-12	2005-12-29	Jane C. Hirsh	Abuse-deterrent drug formulations
WO2006025882A2 (en)	2004-08-25	2006-03-09	The Uab Research Foundation	Absorption enhancers for drug administration
US9895444B2 (en)	2004-08-25	2018-02-20	Aegis Therapeutics, Llc	Compositions for drug administration
EP2158920A1 (en)	2006-06-23	2010-03-03	Aegis Therapeutics LLC	Stabilizing alkylglycoside compositions and methods thereof
US10668060B2 (en)	2009-12-10	2020-06-02	Collegium Pharmaceutical, Inc.	Tamper-resistant pharmaceutical compositions of opioids and other drugs
CN108892709A (zh)	2011-05-18	2018-11-27	欧莫德里斯制药公司	改良的肽药物
ES2906975T3 (es)	2012-11-20	2022-04-21	Eumederis Pharmaceuticals Inc	Productos farmacéuticos de péptidos mejorados
MX360816B (es)	2012-11-20	2018-11-15	Mederis Diabetes Llc	Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina.
WO2014140699A1 (en) *	2013-03-13	2014-09-18	Calyx Chemicals And Pharmaceuticals Ltd	A novel process of liberation of erythromycin and preparation of its salts
PT3155017T (pt)	2014-05-28	2024-05-14	Mederis Diabetes Llc	Farmacêuticos peptídicos melhorados para resistência à insulina
US9737530B1 (en)	2016-06-23	2017-08-22	Collegium Pharmaceutical, Inc.	Process of making stable abuse-deterrent oral formulations
PH12019502594A1 (en)	2017-05-19	2020-10-26	Lunella Biotech Inc	Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
WO2019108729A1 (en)	2017-12-01	2019-06-06	Lunella Biotech, Inc.	Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
WO2019157099A1 (en)	2018-02-06	2019-08-15	Aegis Therapeutics, Llc	Intranasal epinephrine formulations and methods for the treatment of disease
GB2600026B (en)	2018-02-06	2022-10-12	Aegis Therapeutics Llc	Intranasal epinephrine formulations and methods for the treatment of disease
AU2019402099B2 (en) *	2018-12-17	2025-01-23	Lunella Biotech, Inc.	Triple combination therapies for anti-aging
AU2019403048B2 (en) *	2018-12-17	2025-01-23	Lunella Biotech, Inc.	Triple combination therapies for targeting mitochondria and killing cancer stem cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1011117B (de) *	1953-11-16	1957-06-27	Abbott Lab	Verfahren zur Herstellung von reinen stabilen Erythromycin-Saeure-Additionssalzen
FR1179208A (fr) *	1953-11-16	1959-05-21	Abbott Lab	Procédé de préparation de sels d'érythromycine
GB834397A (en) *	1958-07-29	1960-05-04	Lilly Co Eli	Therapeutic compositions comprising erythromycin esters
US4150220A (en) *	1977-02-04	1979-04-17	Pfizer Inc.	Semi-synthetic 4"-erythromycin A derivatives
FR2473525A1 (fr) *	1980-01-11	1981-07-17	Roussel Uclaf	Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments

1984
- 1984-01-06 DK DK5884A patent/DK149776C/da not_active IP Right Cessation
- 1984-12-18 NZ NZ210606A patent/NZ210606A/en unknown
- 1984-12-20 IL IL73885A patent/IL73885A/xx not_active IP Right Cessation
- 1984-12-21 AU AU37059/84A patent/AU565688B2/en not_active Ceased
- 1984-12-21 GB GB08432368A patent/GB2152502B/en not_active Expired
- 1984-12-27 US US06/686,753 patent/US4599326A/en not_active Expired - Fee Related
- 1984-12-28 SE SE8406671A patent/SE461854B/sv not_active IP Right Cessation
- 1984-12-28 BE BE0/214265A patent/BE901411A/fr not_active IP Right Cessation
- 1984-12-28 PT PT79777A patent/PT79777B/pt not_active IP Right Cessation
- 1984-12-28 IS IS2968A patent/IS2968A7/is unknown
- 1984-12-28 ZA ZA8410143A patent/ZA8410143B/xx unknown
- 1984-12-31 NL NL8403979A patent/NL8403979A/nl not_active Application Discontinuation
1985
- 1985-01-02 NO NO850007A patent/NO160263C/no unknown
- 1985-01-02 MA MA20540A patent/MA20316A1/fr unknown
- 1985-01-02 FR FR8500005A patent/FR2557878B1/fr not_active Expired
- 1985-01-03 AT AT0000985A patent/AT386414B/de not_active IP Right Cessation
- 1985-01-03 FI FI850023A patent/FI77249C/fi not_active IP Right Cessation
- 1985-01-04 SU SU853836820A patent/SU1410866A3/ru active
- 1985-01-04 DE DE19853500179 patent/DE3500179A1/de active Granted
- 1985-01-04 KR KR1019850000008A patent/KR900006237B1/ko not_active Expired
- 1985-01-04 PL PL1985251457A patent/PL144349B1/pl unknown
- 1985-01-04 CH CH31/85A patent/CH666275A5/de not_active IP Right Cessation
- 1985-01-04 CA CA000471563A patent/CA1224461A/en not_active Expired
- 1985-01-04 HU HU8537A patent/HU196221B/hu not_active IP Right Cessation
- 1985-01-04 YU YU20/85A patent/YU44485B/xx unknown
- 1985-01-04 ES ES539349A patent/ES8605818A1/es not_active Expired
- 1985-01-04 CS CS8596A patent/CS247191B2/cs unknown
- 1985-01-04 LU LU85721A patent/LU85721A1/fr unknown
- 1985-01-04 IT IT19012/85A patent/IT1184304B/it active
- 1985-01-04 IE IE22/85A patent/IE57967B1/en not_active IP Right Cessation
- 1985-01-05 BG BG068285A patent/BG43189A3/xx unknown
- 1985-01-07 RO RO117230A patent/RO91262B/ro unknown
- 1985-01-07 PH PH31689A patent/PH22471A/en unknown
- 1985-01-07 MX MX203973A patent/MX156277A/es unknown
- 1985-01-07 JP JP60000744A patent/JPS60158197A/ja active Granted
1988
- 1988-10-28 KE KE3841A patent/KE3841A/xx unknown
1989
- 1989-07-21 CY CY1462A patent/CY1462A/en unknown
1990
- 1990-02-15 HK HK115/90A patent/HK11590A/xx unknown

Also Published As

Publication number	Publication date
IL73885A (en)	1988-10-31
IE57967B1 (en)	1993-06-02
PL144349B1 (en)	1988-05-31
DK149776C (da)	1987-04-21
JPS60158197A (ja)	1985-08-19
SE8406671L (sv)	1985-07-07
IE850022L (en)	1985-07-06
NO850007L (no)	1985-07-08
PH22471A (en)	1988-09-12
FR2557878A1 (fr)	1985-07-12
RO91262B (ro)	1987-07-01
IL73885A0 (en)	1985-03-31
SE8406671D0 (sv)	1984-12-28
IT1184304B (it)	1987-10-28
BG43189A3 (en)	1988-04-15
FI77249B (fi)	1988-10-31
KR900006237B1 (ko)	1990-08-27
JPH029040B2 (2)	1990-02-28
AT386414B (de)	1988-08-25
RO91262A (ro)	1987-06-30
CA1224461A (en)	1987-07-21
GB2152502B (en)	1987-10-07
FI850023L (fi)	1985-07-07
NO160263C (no)	1989-03-29
CS247191B2 (en)	1986-12-18
DE3500179C2 (2)	1989-08-24
DK149776B (da)	1986-09-29
KR850005452A (ko)	1985-08-26
AU565688B2 (en)	1987-09-24
DK5884D0 (da)	1984-01-06
US4599326A (en)	1986-07-08
SU1410866A3 (ru)	1988-07-15
YU44485B (en)	1990-08-31
ATA985A (de)	1988-01-15
ZA8410143B (en)	1985-08-28
LU85721A1 (fr)	1985-07-24
IS2968A7 (is)	1985-04-03
DE3500179A1 (de)	1985-07-18
GB8432368D0 (en)	1985-02-06
NO160263B (no)	1988-12-19
YU2085A (en)	1987-12-31
PT79777B (en)	1986-10-21
HUT37628A (en)	1986-01-23
FI850023A0 (fi)	1985-01-03
ES539349A0 (es)	1986-04-01
FI77249C (fi)	1989-02-10
SE461854B (sv)	1990-04-02
MX156277A (es)	1988-08-04
NZ210606A (en)	1987-08-31
FR2557878B1 (fr)	1988-01-15
AU3705984A (en)	1985-07-11
IT8519012A0 (it)	1985-01-04
HU196221B (en)	1988-10-28
PL251457A1 (en)	1985-11-05
KE3841A (en)	1989-04-07
GB2152502A (en)	1985-08-07
HK11590A (en)	1990-02-23
DK5884A (da)	1985-07-07
PT79777A (en)	1985-01-01
BE901411A (fr)	1985-04-16
CH666275A5 (de)	1988-07-15
CY1462A (en)	1989-07-21
MA20316A1 (fr)	1985-10-01
ES8605818A1 (es)	1986-04-01

Legal Events

Date	Code	Title
1988-05-02	BA	A request for search or an international-type search has been filed
1988-07-01	BB	A search report has been drawn up
1988-11-01	BC	A request for examination has been filed
1996-09-02	BV	The patent application has lapsed

Publication	Publication Date	Title
NL8403979A (nl)	1985-08-01	Antibiotische verbinding, werkwijze voor de bereiding daarvan, alsmede preparaten die deze bevatten.
CA1087205A (en)	1980-10-07	2-amino-3-(5-and 6-)benzoylphenylacetic acids, esters and metal salts thereof
EP0094149B1 (en)	1986-09-10	Pharmaceutical compositions containing a complex of iron with n-substituted 3-hydroxypyrid-2-one or -4-one derivatives
LV10458B (en)	1996-02-20	4,13-dioxabicyclo£8.2.1.\|tridecenone derivatives, method and intermediate products for preparation thereof and drugs containing that compounds
SU818492A3 (ru)	1981-03-30	Способ получени деоксинаразино-ВОгО АНТибиОТичЕСКОгО КОМплЕКСА
US4048307A (en)	1977-09-13	Cyclic adenosine monophosphate 8-substituted derivatives
GB1565083A (en)	1980-04-16	Pseudomonic acid amides
IE54520B1 (en)	1989-11-08	Novel-2-beta-d ribofuranosylselenazole-4-carboxamide compounds and methods for their production
CA1111419A (en)	1981-10-27	Lonomycin derivatives
CA1057306A (en)	1979-06-26	Ascochlorin derivatives
IE43106B1 (en)	1980-12-17	Mocimycin derivatives
JPH1045738A (ja)	1998-02-17	抗生物質エポキシキノマイシンｃおよびｄとその製造法ならびに抗リウマチ剤
US4959394A (en)	1990-09-25	Novel Guanidinium aspartates
US3901973A (en)	1975-08-26	Antibiotic everninomicin 1
US4092426A (en)	1978-05-30	Novel aminobenzoic acid derivatives, process for preparing the same and pharmaceutical composition containing the same
JPS5852291A (ja)	1983-03-28	ペニシリン系抗生物質誘導体とその医薬剤
US4096248A (en)	1978-06-20	Sulfonyl containing organic gold glycoside compounds and method of use
JP3406334B2 (ja)	2003-05-12	チロシン特異的リン酸化酵素阻害剤及び制癌剤
US4169891A (en)	1979-10-02	Method for the control of swine dysentery with antibiotic BM123γ and certain derivatives thereof
EP0004270A1 (en)	1979-10-03	Streptovaricin C derivatives, a process for their preparation and antiviral compositions containing them
US4681877A (en)	1987-07-21	Pivaloyloxymethyl 7-β-[2-(2-amino-4-thiazolyl)-2-methoxyiminoacetamido]-3-(2-amino-1,3-thiadiazolyl-5-thiomethyl)-3-cepheme-4-carboxylate and pharmaceutical composition containing the same
JPS6054690A (ja)	1985-03-29	抗生物質ＬＬ−Ｄ０５１３９β
US3501570A (en)	1970-03-17	Chromomycin a3 derivatives and production thereof
CA1074307A (en)	1980-03-25	Antibiotic
EP0257488A2 (en)	1988-03-02	Novel diaminopyrimido[4,5-d]pyrimidine glycoside and glycotide and process